Nuwellis Pediatric Ultrafiltration Case Study Highlights Potential in Cardiorenal Care
Event summary
- Nuwellis presented a case study on pediatric ultrafiltration therapy at ISHLT's annual meeting April 22–25, 2026.
- The study focused on Aquadex SmartFlow® use in chemotherapy-induced dilated cardiomyopathy with fluid overload.
- Results showed improved clinical status pre-transplant and better outcomes post-cardiac transplant.
- Nuwellis aims to establish ultrafiltration as standard care for pediatric cardiorenal patients.
The big picture
This case study positions Nuwellis to capture a niche in pediatric cardiorenal care, where fluid overload remains a critical unmet need. The presentation at ISHLT—a key forum for heart failure specialists—amplifies the company's credibility as it seeks to differentiate Aquadex from diuretic-based approaches. Success here could expand its addressable market beyond adults with heart failure.
What we're watching
- Clinical Adoption
- How quickly pediatric cardiology centers will integrate ultrafiltration into standard protocols.
- Regulatory Pathway
- Whether Nuwellis can secure expanded indications for Aquadex in pediatric populations.
- Competitive Positioning
- The pace at which competitors develop alternative fluid management solutions for children.